

Helsinki, 02 June 2023

**Addressee(s)**

Registrant as listed in Appendix 3 of this decision

**Date of submission of the dossier subject to this decision**

18/11/2021

**Registered substance subject to this decision ("the Substance")**

Substance name: Naphthalene-2,6-dicarboxylic acid

EC/List number: 214-527-0

**Decision number:** Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)

**DECISION ON TESTING PROPOSAL(S)**

Under Article 40 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below by **9 June 2025**.

Requested information must be generated using the Substance unless otherwise specified.

**Information required from all the Registrants subject to Annex IX of REACH**

1. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: OECD TG 414) by oral route, in one species (rat or rabbit)

The reasons for the decision(s) are explained in Appendix 1.

**Information required depends on your tonnage band**

You must provide the information listed above for all REACH Annexes applicable to you in accordance with Articles 10(a) and 12(1) of REACH. The addressee(s) of the decision and their corresponding information requirements based on registered tonnage band are listed in Appendix 3.

You are only required to share the costs of information that you must submit to fulfil your information requirements.

**How to comply with your information requirements**

To comply with your information requirements, you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also **update the chemical safety report**, where relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general requirements for testing and reporting new tests under REACH, see Appendix 4.

**Appeal**

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to <http://echa.europa.eu/regulations/appeals> for further information.

**Failure to comply**

If you do not comply with the information required by this decision by the deadline indicated above, ECHA will notify the enforcement authorities of your Member State.

Authorised<sup>1</sup> under the authority of Mike Rasenberg, Director of Hazard Assessment

Appendix 1: Reasons for the decision

Appendix 2: Procedure

Appendix 3: Addressees of the decision and their individual information requirements

Appendix 4: Conducting and reporting new tests under REACH

---

<sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

## **Appendix 1: Reasons for the decision**

### **Contents**

<b>Reasons for the decision(s) related to the information under Annex IX of REACH .....</b>	<b>4</b>
1. Pre-natal developmental toxicity study.....	4
<b>References .....</b>	<b>6</b>

**Reasons for the decision(s) related to the information under Annex IX of REACH****1. Pre-natal developmental toxicity study**

1 A pre-natal developmental toxicity (PNDT) study (OECD TG 414) in one species is an information requirement under Annex IX, Section 8.7.2.

*1.1. Information provided to fulfil the information requirement*

2 You have submitted a testing proposal for a PNDT study according to the OECD TG 414 by the oral route with the Substance.

3 ECHA requested your considerations for alternative methods to fulfil the information requirement for Developmental toxicity. In your registration dossier, you initially provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. With your comments to the draft decision, you later proposed read-across from a study on the source substance Dimethyl naphthalene-2,6-dicarboxylate (EC 212-661-4). ECHA has taken these considerations into account.

4 ECHA received third party information concerning the testing proposal during the third-party consultation.

5 A third party has indicated that ""Repeated dose toxicity/reproductive developmental toxicity combined study in rats"" (Compound Safety Research Laboratory Co. Ltd, under GLP conditions) included in the Lead dossier, might not be regarded as a guideline compliant pre-natal developmental toxicity-PNDT (OECD 414), but it is roughly equivalent to OECD 422/423 and does provide convincing evidence that developmental toxicity is of low concern and additional toxicological studies in animals are highly unlikely to identify a developmental hazard. As such, ECHA should consider this developmental toxicity screening study as fulfilling this data requirement. The full study report is publicly available, the robust study summary is contained in Lead dossier."

6 ECHA notes that an OECD 422 screening study is not a test method that corresponds to the standard information requirement of Annex IX, Section 8.7.2 for a pre-natal developmental toxicity study (OECD TG 414), because it does not provide equivalent information. The screening study does not cover key parameters of a pre-natal developmental toxicity study such as examinations of the foetuses for skeletal and visceral malformations.

7 Regarding the proposed adaptation of the required information by means of grouping and read-across, ECHA finds that the information submitted in the comments to the draft decision do not meet the requirements for adaptation under Annex XI, Section 1.5, of the REACH Regulation. This is for the following reasons.

*1.1.1. Read-across adaptation rejected*

8 Annex XI, Section 1.5. specifies two conditions which must be fulfilled whenever a read-across approach is used. Firstly, there needs to be structural similarity between substances which results in a likelihood that the substances have similar physicochemical, toxicological and ecotoxicological properties so that the substances may be considered as a group or category. Secondly, it is required that the relevant properties of a substance within the group may be predicted from data for reference substance(s) within the group.

9 Additional information on what is necessary when justifying a read-across approach can be found in the Guidance on IRs and CSA, Chapter R.6. and related documents (RAAF, 2017; RAAF UVCB, 2017).

*Absence of read-across documentation*

- 10 Annex XI, Section 1.5. requires that whenever read-across is used adequate and reliable documentation of the applied method must be provided. Such documentation must include an explanation and supporting information (for example from bridging studies allowing comparison of results) why the properties of the Substance may be predicted from information on the source substance(s).
- 11 However, you have not provided any documentation to explain why the information on the analogue substance is relevant for the Substance and why the properties of the Substance may be predicted from information on the source substance.
- 12 In the absence of such documentation, the properties of the Substance cannot be reliably predicted from the data on the source substance.
- 13 Therefore, your read-across approach under Annex XI, Section 1.5. is rejected and the information requirement is not fulfilled.
- 14 ECHA considers that a PNDT study in a first species is necessary.

*1.2. Specification of the study design*

- 15 You proposed testing in the rat as a first species. You may select between the rat or the rabbit because both are preferred species under the OECD TG 414 (Guidance on IRs & CSA, Section R.7.6.2.3.2.).
- 16 You did not specify the route for testing. The oral route of administration is the most appropriate to investigate reproductive toxicity (Guidance on IRs & CSA, Section R.7.6.2.3.2.).

*1.3. Outcome*

- 17 Your testing proposal is accepted under Article 40(3)(a) and you are requested to conduct the test, as specified above.

## References

The following documents may have been cited in the decision.

### **Guidance on information requirements and chemical safety assessment (Guidance on IRs & CSA)**

- Chapter R.4 Evaluation of available information; ECHA (2011).
- Chapter R.6 QSARs, read-across and grouping; ECHA (2008).  
Appendix to Chapter R.6 for nanoforms; ECHA (2019).
- Chapter R.7a Endpoint specific guidance, Sections R.7.1 – R.7.7; ECHA (2017).  
Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
- Chapter R.7b Endpoint specific guidance, Sections R.7.8 – R.7.9; ECHA (2017).  
Appendix to Chapter R.7b for nanomaterials; ECHA (2017).
- Chapter R.7c Endpoint specific guidance, Sections R.7.10 – R.7.13; ECHA (2017).  
Appendix to Chapter R.7a for nanomaterials; ECHA (2017).  
Appendix R.7.13-2 Environmental risk assessment for metals and metal compounds; ECHA (2008).
- Chapter R.11 PBT/vPvB assessment; ECHA (2017).
- Chapter R.16 Environmental exposure assessment; ECHA (2016).

**Guidance on data-sharing**; ECHA (2017).

**Guidance for monomers and polymers**; ECHA (2012).

**Guidance on intermediates**; ECHA (2010).

All guidance documents are available online: <https://echa.europa.eu/guidance-documents/guidance-on-reach>

### **Read-across assessment framework (RAAF)**

- RAAF, 2017 Read-across assessment framework (RAAF); ECHA (2017)
- RAAF UVCB, 2017 Read-across assessment framework (RAAF) – considerations on multi- constituent substances and UVCBs); ECHA (2017).

The RAAF and related documents are available online:

<https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

### **OECD Guidance documents (OECD GDs)**

- OECD GD 23 Guidance document on aquatic toxicity testing of difficult substances and mixtures; No. 23 in the OECD series on testing and assessment, OECD (2019).
- OECD GD 29 Guidance document on transformation/dissolution of metals and metal compounds in aqueous media; No. 29 in the OECD series on testing and assessment, OECD (2002).
- OECD GD 150 Revised guidance document 150 on standardised test guidelines for evaluating chemicals for endocrine disruption; No. 150 in the OECD series on testing and assessment, OECD (2018).
- OECD GD 151 Guidance document supporting OECD test guideline 443 on the extended one-generation reproductive toxicity test; No. 151 in the OECD series on testing and assessment, OECD (2013).

**Appendix 2: Procedure**

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 24 May 2022.

ECHA held a third-party consultation for the testing proposal(s) from 16 June 2022 until 1 August 2022. ECHA received information from third parties (see corresponding Appendix) ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

The deadline of the decision is set based on standard practice for carrying out OECD TG tests. It has been exceptionally extended by 12 months from the standard deadline granted by ECHA to take into account currently longer lead times in contract research organisations.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA took into account your comments and did not amend the request.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

**Appendix 3: Addressee(s) of this decision and their corresponding information requirements**

In accordance with Articles 10(a) and 12(1) of REACH, the information requirements for individual registrations are defined as follows:

- the information specified in Annexes VII, VIII and IX to REACH, for registration at 100-1000 tpa.

<b>Registrant Name</b>	<b>Registration number</b>	<b>Highest REACH Annex applicable to you</b>
[REDACTED]	[REDACTED]	[REDACTED]

Where applicable, the name of a third-party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.

## Appendix 4: Conducting and reporting new tests for REACH purposes

### 1. Requirements when conducting and reporting new tests for REACH purposes

#### 1.1. Test methods, GLP requirements and reporting

- (1) Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.
- (2) Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.
- (3) Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries<sup>2</sup>.
- (4) Under the introductory part of Annexes VII/VIII/IX/X to REACH, where a test method offers flexibility in the study design, for example in relation to the choice of dose levels or concentrations, the chosen study design must ensure that the data generated are adequate for hazard identification and risk assessment.

#### 1.2. Test material

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test Material) which must be relevant for all the registrants of the Substance.

- (1) Selection of the Test material(s)  
The Test Material used to generate the new data must be selected taking into account the following:
  - the variation in compositions reported by all members of the joint submission,
  - the boundary composition(s) of the Substance,
  - the impact of each constituent/ impurity on the test results for the endpoint to be assessed. For example, if a constituent/ impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test Material must contain that constituent/ impurity.
- (2) Information on the Test Material needed in the updated dossier
  - You must report the composition of the Test Material selected for each study, under the "Test material information" section, for each respective endpoint study record in IUCLID.
  - The reported composition must include all constituents of each Test Material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test Material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers<sup>3</sup>.

<sup>2</sup> <https://echa.europa.eu/practical-guides>

<sup>3</sup> <https://echa.europa.eu/manuals>